|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal management of diabetic kidney disease (DKD) with intensive glycemic control and administration of agents blocking the renin-angiotensinaldosterone- system, the residual risk for nephropathy progression to end-stage-renal-disease (ESRD) remains high.
|
29792136 |
2019 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The presumed superiority of renin-angiotensin-aldosterone system (RAAS)-blocking agents over other antihypertensive agents in patients with diabetes to delay development of end-stage kidney disease (ESKD) has recently been challenged.
|
29106631 |
2018 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this pooled analysis of four prospective studies in CKD patients treated with drugs inhibiting the renin-angiotensin system, we compared the risk of all-cause mortality, fatal and non-fatal cardiovascular (CV) events and end-stage renal disease (ESRD) between patients with (n = 693) and without diabetes (n = 1481) stratified by proteinuria level (<0.15, 0.15-0.49, 0.5-1 and >1 g/day).
|
29509925 |
2018 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Obesity, whether defined by BMI or BF%, was not associated with a significantly increased risk of ESRD in Cox proportional hazards models that adjusted for age, sex, diabetes mellitus, cardiovascular disease, estimated glomerular filtration rate, urine protein:creatinine ratio, high-sensitivity C-reactive protein, and use of renin-angiotensin-aldosterone system inhibitors or statins, accounting for the competing risk for mortality (subdistribution HR: 1.15; 95% CI: 0.62, 2.14 for BMI-defined obesity and subdistribution HR: 0.84, 95% CI: 0.54, 1.29 for BF%-defined obesity, respectively).
|
30321257 |
2018 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
With the realization that lowering blood pressure, including with renin-angiotensin system blockade, failed to reliably prevent end-stage kidney disease, studies now are analyzing longer-term effects of hypertension control on survival in chronic kidney disease.
|
28087008 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mid-regional pro-atrial natriuretic peptide (MR-proANP), N-terminal prohormone of brain natriuretic peptide (NT-proBNP), vasopressin (AVP) and copeptin (CT-proAVP), metanephrines and normetanephrines, renin and aldosterone, standard transthoracic echocardiography and diameter of vena cava inferior (VCID) were performed in 20 patients with end stage renal disease (CKD5D) before and after HD and were stratified in residual excretion (RE, less or more 0.5 l) and ultrafiltration rate (UF, less or more 2 l).
|
28558715 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite optimal therapy of diabetic nephropathy with agents blocking the renin-angiotensin-aldosterone system, the residual risk of nephropathy progression to end-stage renal disease (ESRD) remains high.
|
28520568 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The progression to ESRD in patients with obesity and diabetes continues despite widespread use of inhibitors of the renin-angiotensin-aldosterone system (RAAS) along with aggressive blood pressure and glycemic control in these high-risk populations.
|
28341271 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the benefits derived from strict control of glucose and blood pressure, as well as inhibition of renin-angiotensin-aldosterone system, many patients continue to enter into ESRD.
|
28386567 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Weight loss, either induced by diet or bariatric surgery, and renin-angiotensin blockers are effective treatments to slow progression, but a significant proportion of cases will develop end-stage renal disease.
|
27414023 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Angiotensin receptor blockers are associated with lower mortality than ACE inhibitors in predialytic stage 5 chronic kidney disease: A nationwide study of therapy with renin-angiotensin system blockade.
|
29216260 |
2017 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conclude that heterozygous substitutions at the AGT M235T and REN A/G(I8-83) loci correlate significantly with ESRD in a north Indian population.
|
25660845 |
2015 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The renin-angiotensin-aldosterone system blockade is central to the current treatment of patients with chronic kidney disease (CKD) for the renoprotective effects aimed to prevent or slow progression to end-stage renal disease (ESRD).
|
25176603 |
2015 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
A number of genetic variations involved in renin-angiotensin-aldosterone system (RAAS) pathway genes have clinical or physiological impacts on pathogenesis of hypertension-induced ESRD in ADPKD.
|
25001132 |
2014 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Analysis of genetic factors connected with the renin-angiotensin system that influences the survival of the patients with end-stage kidney disease supports the ongoing search for improved outcomes.
|
25076182 |
2014 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
The evidence for a beneficial renoprotective effect of renin-angiotensin-aldosterone system (RAAS) blockade by angiotensin-converting enzyme (ACE) inhibition and/or angiotensin receptor blockers (ARBs) is well established in AS and recent evidence has shown that it can significantly delay the time to onset of renal replacement therapy and ESKD.
|
22903660 |
2013 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients treated with renin-angiotensin system blockade or calcium channel blockers during follow-up had significantly later onset of ESRD by 4.3 years and 2.1 years, respectively.
|
22297678 |
2012 |
|
Chronic kidney disease stage 5
|
0.100 |
Biomarker
|
disease |
BEFREE |
Renin-angiotensin system (RAS) blockade is the standard of care; however, a significant proportion of patients progress to ESRD.
|
21144773 |
2012 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphisms of the renin-angiotensin-aldosterone system in Chinese patients with end-stage renal disease secondary to IgA nephropathy.
|
21163122 |
2010 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system polymorphisms: a risk factor for progression to end-stage renal disease in vesicoureteral reflux patients.
|
19288324 |
2009 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We examined an association of the three renin-angiotensin system (RAS) gene polymorphisms with renal disease and progression to ESRD in dialyzed patients.
|
16384824 |
2006 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The role of interaction of polymorphisms in the Renin-Angiotensin-System (RAS) with angiotensin converting enzyme (ACE) or angiotensin receptor (AGTR1) inhibitors (RAS inhibitors) is unknown, as is the role of such therapy in end stage renal disease (ESRD) patients.
|
15946912 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, this polymorphism may interact with other polymorphisms within the renin-angiotensin system, leading to high risk of ESRD.
|
16088846 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease.
|
16105049 |
2005 |
|
Chronic kidney disease stage 5
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Renin-angiotensin system gene polymorphisms: its impact on IgAN and its progression to end-stage renal failure among Chinese in Singapore.
|
15153745 |
2004 |